Salmedix was a start-up biotechnology firm focused on discovering and developing minimally-toxic therapies to treat cancers, particularly those that affect the growing global geriatric population. The company was acquired by Cephalon in May 2005.
NovaCardia was a pharmaceutical company focused on developing and commercializing a portfolio of novel small molecule drugs for cardiovascular care. NovaCardia was acquired by Merck in 2007.
Myogen, a University of Colorado Medical Center-based company, developed therapeutics for the treatment of heart disease. The company's strategy was to leverage its molecular and clinical expertise in heart muscle disease to discover new therapeutic targets for drug development, and develop and add value to in-licensed products. Myogen had an initial public offering in 2003, then was acquired by Gilead Pharmaceuticals in 2006.
Inspire Pharmaceuticals discovered and developed breakthrough products to treat diseases involving impaired hydration of the body's mucosal surfaces such as chronic bronchitis and dry eye disease. The products were targeted at disorders with high unmet medical needs representing large, near-term market opportunities. Inspire had an initial public offering in 2000 and was acquired by Merck in 2011.
Dynavax Technologies discovers and develops products to prevent and treat infectious and inflammatory diseases. Its clinical-stage product candidates include HEPLISAV ™ Hepatitis B Vaccine, Universal Flu Vaccine , TLR Inhibitor for Lupus and Hepatitis B Therapy. The company partners with AstraZeneca, GlaxoSmithKline and other pharmaceutical companies.
Cubist Pharmaceuticals is focused on the research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIND (daptomycin for injection), the first antibiotic in a new class of anti-infectives called lipopeptides. The Cubist product pipeline includes its lipopeptide program and its natural products screening program.
Coulter Pharmaceutical developed monoclonal antibody-based anti-cancer drugs that hone in on tumor cells without devastating surrounding healthy tissues. The company's flagship product was the first anti-B1 antibody-based therapy for the treatment of non-Hodgkin's lymphoma. The company merged with Corixa in December 2000, which was subsequently acquired by GlaxoSmithKline.
Corixa was formed in 1994 to develop vaccines and therapeutic products for cancer and infectious diseases based on novel approaches to immunization, stimulation, and culture of cytotoxic T cells and T helper cells. Corixa had an initial public offering in 1997, then was acquired by GlaxoSmithKline in 2005.
COR was funded to develop and commercialize innovative pharmaceutical products for the treatment and prevention of severe cardiovascular diseases, such as unstable angina, acute ischemic coronary syndrome and stroke. COR went public in 1991 and was acquired by Millennium in 2001.
Cell Genesys is focused on the development and commercialization of biological therapies for patients with cancer. The company is currently pursuing two clinical-stage product platforms — GVAX(R) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include GVAX immunotherapy for prostate cancer, GVAX immunotherapy for pancreatic cancer and leukemia, and a CG0070 oncolytic virus therapy for bladder cancer.